Aurinia Pharmaceuticals Stock News

The shares of the commercial-stage biopharmaceutical company Aurinia Pharmaceuticals <> have added more than a tenth on Wednesday to record the biggest intraday gain in over…

Over the past 3 months, 4 analysts have published their opinion on Aurinia Pharmaceuticals (NASDAQ:AUPH) stock. These analysts are typically employed by large Wall Street banks and tasked with underst

Over the past 3 months, 4 analysts have published their opinion on Aurinia Pharmaceuticals (NASDAQ: AUPH ) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a company''s business to predict how a stock will trade over the upcoming year. Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 0 4 0 0 0 Last 30D 0 1 0 0 0 1M Ago 0 2 0 0 0 2M Ago 0 0 0 0 0 3M Ago 0 1 0 0 0 These 4 analysts have an average price target of $27.75 versus the current price of Aurinia Pharmaceuticals at $10.67, implying upside. Below is a summary of how these 4 analysts rated Aurinia … Full story available on Benzinga.com

Raymond James cut the price target on Ciena Corporation (NYSE: CIEN) from $80 to $75. Ciena shares fell 10.9% to close at $58.76 on Monday. Telsey Advisory Group cut Capri Holdings Limited (NYSE:

NEW YORK--(BUSINESS WIRE)--WHY: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) resulting from allegations that Aurinia may have issued materially misleading business information to the investing public. SO WHAT: If you purchased Aurinia securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arr

Aurinia Pharmaceuticals (AUPH) rose 2.8% on a report that a European-based investor group is campaigning for the biotech to begin a strategic review.Aurinia holders, led…

Aurinia Pharmaceuticals, along with biotechs in general, has been beaten down recently.

Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (the “Company”) today announced that members of the executive management team will give corporate presenta

VICTORIA, British Columbia--(BUSINESS WIRE)--Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (the “Company”) today announced that members of the executive management team will give corporate presentat

NEW YORK, March 2, 2022 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Aurinia Pharmaceuticals Inc. ("Aurinia" or the "Company") (NASDAQ: AUPH). Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 7980….

A whale with a lot of money to spend has taken a noticeably bullish stance on Aurinia Pharmaceuticals . Looking at options history for Aurinia Pharmaceuticals (NASDAQ: AUPH ) we detected 10 strange trades. If we consider the specifics of each trade, it is accurate to state that 70% of the investors opened trades with bullish expectations and 30% with bearish. From the overall spotted trades, 3 are puts, for a total amount of $106,666 and 7, calls, for a total amount of $216,391. What''s The Price Target? Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $5.0 to $13.0 for Aurinia Pharmaceuticals over the last 3 months. Volume … Full story available on Benzinga.com

Takeover speculation has swirled since late 2019 when the company''s lead drug proved to be an effective treatment for lupus nephritis.

A problematic impediment to the sale of Aurinia Pharma has surfaced: The patent life of its drug might not be as strong or long as it hoped.

In the latest trading session, 1.35 million Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) shares changed hands as the company’s beta touched 0.85. With the company’s most recent per share price at $12.09 changed hands at -$0.21 or -1.71% at last look, the market valuation stands at $1.57B. AUPH’s current price is a discount, trading about -180.98% off … Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH): The Stock For Success Over The Next Few Months Read More »

Aurinia topped fourth-quarter expectations Monday, but AUPH stock plummeted on lackluster guidance for lupus treatment Lupkynis.